pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News · Rare Disease
856
stories
May 11, 26
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
stat
May 11, 26
Animal skin disease confirmed in clusters of European men who have sex with men
stat
May 8, 26
Spain readies for evacuations as a hantavirus-hit cruise ship heads for the Canary Islands
stat
May 8, 26
Trump reportedly plans to fire FDA Commissioner Makary
stat
May 8, 26
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
onclive
May 8, 26
Former FDA leaders, pharma speak out on mifepristone
stat
May 8, 26
The biotechs wear Prada
stat
May 8, 26
STAT+: The biotech news you need to read today
stat
May 8, 26
Lilly, Gilead lead pharma’s M&A boom
biopharma dive
May 8, 26
Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting
stat
May 8, 26
Why we left the FDA: Six former officials share their stories
stat
May 7, 26
Key takeaways from WHO briefing on hantavirus cruise ship outbreak
stat
May 7, 26
Science is becoming less disruptive. Is an aging workforce to blame?
stat
May 7, 26
Official leading CDC’s cruise ship program retires
stat
May 7, 26
Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.
onclive
May 7, 26
Angelini to buy Catalyst in $4B play for rare neuro drugs
biopharma dive
May 7, 26
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
stat
May 7, 26
STAT+: FDA revisits a rare cancer treatment it rejected a few months ago
stat
May 7, 26
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
stat
May 7, 26
STAT+: Next-gen Duchenne drug from Entrada disappoints
stat
May 7, 26
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
endpoints
May 7, 26
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
stat
May 7, 26
Cruise ship hantavirus outbreak worries experts, though they discount pandemic fears
stat
May 6, 26
STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
stat
May 6, 26
Disease Assessment and Mutational Testing in Progressive CLL
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 6, 26
STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
stat
May 5, 26
Vertex earnings get muted investor response
biopharma dive
May 4, 26
With $97M, Latus pursues a different kind of Huntington’s gene therapy
biopharma dive
May 4, 26
UCB to acquire maker of antibody treatments for autoimmune diseases
stat
← prev
page 27 of 29
next →
